Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy.

Trial Profile

Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2018

At a glance

  • Drugs Eribulin (Primary) ; Trastuzumab
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 May 2018 Status changed from active, no longer recruiting to completed.
    • 08 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Jul 2018.
    • 11 Apr 2017 Planned End Date changed from 1 Aug 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top